Last reviewed · How we verify
SPR720 500 mg
SPR720 500 mg is a Small molecule drug developed by Spero Therapeutics. It is currently in Phase 2 development.
At a glance
| Generic name | SPR720 500 mg |
|---|---|
| Sponsor | Spero Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease (PHASE2)
- A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants (PHASE1)
- Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPR720 500 mg CI brief — competitive landscape report
- SPR720 500 mg updates RSS · CI watch RSS
- Spero Therapeutics portfolio CI
Frequently asked questions about SPR720 500 mg
What is SPR720 500 mg?
SPR720 500 mg is a Small molecule drug developed by Spero Therapeutics.
Who makes SPR720 500 mg?
SPR720 500 mg is developed by Spero Therapeutics (see full Spero Therapeutics pipeline at /company/spero-therapeutics).
What development phase is SPR720 500 mg in?
SPR720 500 mg is in Phase 2.
Related
- Manufacturer: Spero Therapeutics — full pipeline
- Compare: SPR720 500 mg vs similar drugs
- Pricing: SPR720 500 mg cost, discount & access